The risk of dying during pregnancy is negligible for the average Danish woman, but if the woman in question has epilepsy, the probability must be multiplied by five.
This short review summarizes the history of use of fenfluramine from the initial clinical observations followed by preclinical studies and subsequent successful clinical trial.
These preliminary data point to a favorable cognitive profile of brivaracetam similar to its precursor levetiracetam. Objective gains in attention and executive functions were accompanied by self-reported improvements in concentration and comprehension. Future studies with larger sample sizes and better control conditions are needed to confirm these findings.
Pediatric Epilepsy
Ovid Therapeutics Inc. announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies.
Pediatric Epilepsy
Neurelis, Inc. announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCOTM (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience increased bouts of seizure activity, also known as cluster or acute repetitive seizures.
History of depression and psychosis increased risk of developing intolerable psychiatric and behavioral side effects to antiepileptic drugs. The probability of experiencing intolerable psychiatric and behavioral side effects increased for a patient taking levetiracetam or zonisamide if the patient experienced intolerable psychiatric and behavioral side effects to another antiepileptic drugs. Our results may be clinically useful for predicting intolerable psychiatric and behavioral side effects associated with certain antiepileptic drugs.
Pediatric Epilepsy
A research team led by CURE Grantee Dr. Jeong Ho Lee identified a mutation in the BRAF gene that causes intrinsic epileptogenicity in pediatric brain tumors.
